Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis

被引:57
|
作者
Bodri, Daniel [1 ,2 ]
Sunkara, Sesh Kamal [3 ]
Coomarasamy, Arri [4 ]
机构
[1] Clin Eugin, Barcelona 08029, Spain
[2] Univ Autonoma Barcelona, Dept Pediat Obstet & Ginecol & Med Prevent, E-08193 Barcelona, Spain
[3] Guys & St Thomas Hosp Natl Hlth Serv Fdn Trust, Assisted Concept Unit, London, England
[4] Birmingham Womens Hosp, Acad Dept, Birmingham, W Midlands, England
关键词
Oocyte donation; GnRH antagonist; GnRH agonist; COH; meta-analysis; in vitro fertilization; GNRH ANTAGONIST; DONATION CYCLES; PREGNANCY RATES; STIMULATION; PROTOCOL; IVF; PROGRAM; HCG;
D O I
10.1016/j.fertnstert.2010.06.068
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare GnRH agonists and antagonists in oocyte-donation IVF treatment cycles by a systematic review and meta-analysis of trials. Design: Systematic review and meta-analysis of randomized clinical trials (RCT). Systematic literature searches were conducted, and all randomized trials that compared GnRH agonists with antagonists in oocyte-donation IVF treatment cycles were included. Study selection, quality appraisal, and data extractions were performed independently and in duplicate. Setting: Tertiary fertility center. Patient(s): A total of 1,024 oocyte donors treated in eight RCTs. Intervention(s): Comparison of GnRH agonists versus antagonists in oocyte-donation IVF treatment. Main Outcome Measure(s): Ongoing pregnancy, oocytes retrieved, duration of stimulation, gonadotropin consumption, and ovarian hyperstimulation syndrome incidence (OHSS) per randomized oocyte donor. Result(s): Meta-analysis of these studies showed no significant difference in ongoing pregnancy rate between the GnRH agonists and antagonists (risk ratio [RR] 1.15, 95% confidence interval [CI] 0.97 to 1.36). The duration of stimulation was significantly lower with the GnRH antagonist protocol (weighed mean difference [WMD] -0.90 days, 95% CI -1.61 to -0.20). No significant differences were observed in the number of oocytes retrieved (WMD -0.60, 95% CI -2.26 to +1.07), gonadotropin consumption (WMD -264 IU, 95% CI -682 to +154), or OHSS incidence (RR 0.62, 95% CI 0.18 to 2.15). Conclusion(s): No significant differences were observed in ongoing pregnancy rate or the number of retrieved oocytes after donor stimulation with GnRH agonist or antagonist protocols. (Fertil Steril(R) 2011;95:164-9. (C) 2011 by American Society for Reproductive Medicine.)
引用
收藏
页码:164 / 169
页数:6
相关论文
共 50 条
  • [1] Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis
    Senra, J. C.
    Roque, M.
    Talim, M. C. T.
    Reis, F. M.
    Tavares, R. L. C.
    [J]. ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2018, 51 (01) : 77 - 86
  • [2] Gonadotropin-releasing hormone: An update review of the antagonists versus agonists
    Van Poppel, Hein
    Klotz, Laurence
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 (07) : 594 - 601
  • [3] A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer
    Sciarra, Alessandro
    Fasulo, Andrea
    Ciardi, Antonio
    Petrangeli, Elisa
    Gentilucci, Alessandro
    Maggi, Martina
    Innocenzi, Michele
    Pierella, Federico
    Gentile, Vincenzo
    Salciccia, Stefano
    Cattarino, Susanna
    [J]. MEDICINE, 2016, 95 (27)
  • [4] Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis
    Li, Zhen-Yu
    Dong, Ying-Li
    Cao, Xiao-Zhong
    Ren, Sha-Sha
    Zhang, Zhen
    [J]. MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY, 2022, 29 (09): : 1093 - 1100
  • [5] Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists
    Saadat, P
    Boostanfar, R
    Slater, CC
    Tourgeman, DE
    Stanczyk, FZ
    Paulson, RJ
    [J]. FERTILITY AND STERILITY, 2004, 82 (01) : 167 - 171
  • [6] Gonadotropin-releasing hormone antagonists in controlled ovarian stimulation
    Diedrich, Klaus
    Felberbaum, Ricardo
    Al-Hasani, Safaa
    [J]. GYNAKOLOGE, 2020, 53 (08): : 517 - 521
  • [7] Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the control ovarian hyperstimulation cycles.
    Ma, C.
    Qiao, J.
    Liu, P.
    Wang, C.
    [J]. FERTILITY AND STERILITY, 2006, 86 : S163 - S163
  • [8] Ovarian Hyperstimulation Syndrome Prevention Strategies: Use of Gonadotropin-Releasing Hormone Antagonists
    Griesinger, Georg
    [J]. SEMINARS IN REPRODUCTIVE MEDICINE, 2010, 28 (06) : 493 - 499
  • [9] Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis
    Kunath, Frank
    Borgmann, Hendrik
    Bluemle, Anette
    Keck, Bastian
    Wullich, Bernd
    Schmucker, Christine
    Sikic, Danijel
    Roelle, Catharina
    Schmidt, Stefanie
    Wahba, Amr
    Meerpohl, Joerg J.
    [J]. BMJ OPEN, 2015, 5 (11):
  • [10] Defining the best protocol of controlled ovarian hyperstimulation for intrauterine insemination: A role for gonadotropin-releasing hormone antagonists?
    Somigliana, E.
    Crosignani, P. G.
    [J]. FERTILITY AND STERILITY, 2006, 86 : S406 - S406